ql0605
Chemotherapy-Induced Febrile Neutropenia
Qilu Pharmaceutical Co., Ltd.protein_peptidePhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 95/ 100
Competitive context
17 Active assets in the Chemotherapy-Induced Febrile Neutropenia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
f-627 EVIVE Biotechnology | Phase 3 | BBB |
PEGFILGRASTIM Affiliated Hospital of North Sichuan Medical College | Phase 4 | BBB |
FILGRASTIM Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 4 | BBB |
Cefepime Hospital Universitari Vall d'Hebron Research Institute | Phase 4 | BB |
Spi-2012 Spectrum Pharmaceuticals, Inc | Phase 3 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →